News
-
-
REGULATED PRESS RELEASE
Trading update
Gimv reports active start to fiscal year with new investments and exits, showcasing accelerated growth strategy and robust financing capacity in challenging market. Portfolio performance remains strong, leading to positive EBITDA growth and portfolio return of 4.7% in Q1 2025 -
-
PRESS RELEASE
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Innate Pharma publie le nombre d'actions et de droits de vote au 1er septembre 2025 selon les régulations AMF. Détails du capital social et des droits de vote -
PRESS RELEASE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Innate Pharma releases the total number of shares (92,185,473 ordinary shares, 6,419 Preferred Shares 2016, 7,581 Preferred Shares 2017) and voting rights (92,962,943 theoretical, 92,944,368 exercisable) as of September 1, 2025 in compliance with regulations -
-
-
-
-
PRESS RELEASE
Financial year 2024/25: strong performance, on track to deliver mid-term targets
dormakaba Holding AG reports strong financial performance for the financial year 2024/25, on track to achieve mid-term targets. Adjusted net sales growth, improved EBITDA margin, and strategic advancements highlighted
